🕒 Last update: loading…21/11/2026

Stock Altimmune, Inc. ALT

Altimmune, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -8.25%

Price change 2019 → 2020: 496.83%

Price change 2020 → 2021: -18.79%

Price change 2021 → 2022: 79.59%

Price change 2022 → 2023: -31.61%

Price change 2023 → 2024: -35.91%

Price change 2024 → 2025: -49.93%

Price change 2025 → 2026: -43.49%

Price change 2026 (year to date): -41.88%

Financial growth

Revenue CAGR (8 years): -54.61%

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.16

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -2.62

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 40.35% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Altimmune, Inc.–0.16−34.0 %🔒
Agenus Inc.2.7–+26.5 %–
LNA Santé S.A.10.72.75+10.4 %–
Emergent BioSolutions Inc.4.01.09+6.6 %–
Eurobio Scientific S.A.37.00.09+22.1 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Altimmune, Inc. over the latest fiscal years.

Revenue
41,000 USD
fiscal year 2025
Net income
-88.1 m USD
fiscal year 2025
Net margin
-214,861.0 %
fiscal year 2025
Average annual growth
-65.3 %
Revenue growth over 5 years
Average annual growth
-42.6 %
Revenue growth over 10 years
Market cap
320 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20208.2 m-49.0 m-599.2 %n/a
20214.4 m-97.1 m-2,201.6 %-46.1 %
2022-68,000-84.7 m124,577.9 %-101.5 %
2023426,000-88.4 m-20,762.2 %n/a
202420,000-95.1 m-475,295.0 %-95.3 %
202541,000-88.1 m-214,861.0 %+105.0 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Altimmune, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
1.04
risk zone (below 1.81)
Piotroski Score
3 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-0.07 x
net cash
Fiscal year20212022202320242025
Cash and investments190 m185 m198 m132 m273 m
Total Debt1.5 m1.1 m671,0001.7 m35.7 m
Net Debt-189 m-110 m-134 m-35.2 m-8.1 m
Equity199 m185 m194 m124 m225 m
Total assets219 m207 m211 m139 m280 m
Operating cash flow-78.2 m-62.6 m-75.8 m-79.8 m-67.5 m
Investments (capex)12.1 m126,00047,000011,000
Free cash-flow-90.5 m-62.7 m-75.9 m-79.8 m-67.5 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-1.96 x
Price / book value0.65 x
Return on Equity (ROE)-29.3 %
Return on Invested Capital (ROIC)-23.8 %
Debt / equity0.08 x
Current ratio23.93 x
Interest coverage-27.65 x
Free cash-flow yield-37.4 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Altimmune, Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Altimmune, Inc.320 mn/a-214,861.0 %
Arbutus Biopharma Corporation ABUS810 m4.9-237.9 %
Assembly Biosciences, Inc. ASMB432 m20.7-8.5 %
Aligos Therapeutics, Inc. ALGS13.1 mn/a-1,106.7 %
Enanta Pharmaceuticals, Inc. ENTA320 mn/a-125.4 %
Vir Biotechnology, Inc. VIR1.7 bnn/a-638.9 %
Indaptus Therapeutics, Inc. INDP359 mn/a0.0 %
Structure Therapeutics Inc. GPCR1.2 bnn/a0.0 %
Biomea Fusion, Inc. BMEA42.3 mn/a0.0 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Altimmune, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
15 analysts

Breakdown of ratings

strong buy 0buy 12hold 3sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 9 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Altimmune, Inc.

Free float
94.4 %
share of freely traded shares
Large funds tracked
23
hold the stock as of 2026Q2
Executives (insiders)
5 / 0
5 purchases, 0 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
State Street24.2 m73.6 m0.0 %+238.6 %2026Q2
BlackRock20.4 m62.0 m0.0 %+59.3 %2026Q2
Vanguard Group9.5 m34.3 m0.0 %+48.9 %2025Q4
Marshall Wace6.8 m20.8 m0.0 %+70.3 %2026Q2
Viking Global Investors6.7 m20.4 m0.1 %n/a2026Q2
Geode Capital Management5.0 m15.2 m0.0 %+61.3 %2026Q2
Millennium Management3.3 m10.1 m0.0 %+1.6 %2026Q2
Two Sigma Investments2.4 m7.2 m0.0 %-3.9 %2026Q2

Latest insider transactions

DatePersonSideAmount
18/11/2026Menziuso Richard Thomaspurchase14,187 USD
13/11/2026Weaver Gregory Lpurchase16,200 USD
13/11/2026Pisano Waynepurchase16,350 USD
13/11/2026Durso Jerome Benedictpurchase49,694 USD
13/08/2026Durso Jerome Benedictpurchase44,250 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 26/05/2017
ISIN code
US02155H2004
Workforce
59
full-time employees
Chief executive
Vipin K. Garg

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Altimmune, Inc.

What is the Altimmune, Inc. share price?

Latest recorded price: 1.65 USD on 13/11/2026, for a market cap of 320 m USD.

What is the revenue of Altimmune, Inc.?

41,000 USD for fiscal year 2025, with net income of -88.1 m USD (net margin -214,861.0 %).

What do analysts say about Altimmune, Inc.?

Out of 15 analysts: 12 buy or strong buy, 3 hold, 0 sell or strong sell.

Is Altimmune, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US02155H2004).

How many employees does Altimmune, Inc. have?

59 full-time employees according to the latest published profile.

Who runs Altimmune, Inc.?

Vipin K. Garg is the company's chief executive.

Which large funds own Altimmune, Inc.?

As of 2026Q2, among the large funds tracked: State Street, BlackRock, Vanguard Group, Marshall Wace, Viking Global Investors.

07

Similar stocks